Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Cytokinetics (CYTK)

Nasdaq Health Care Biotechnology S&P MidCap 400
$53.69
-1.86 (-3.35%)
Close of Nov 06, 2026 · end-of-day data
Source: Cytokinetics's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 09, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$106.41M$13.37M$31.50M$26.87M$55.83M$70.43M$94.59M$7.53M$18.47M$88.04M
Research & development$59.90M$90.30M$89.14M$86.12M$96.95M$159.94M$240.81M$330.12M$339.41M$416.03M
Operating income$18.69M-$113.40M-$88.92M-$98.87M-$93.94M-$186.31M-$324.20M-$496.20M-$536.25M-$612.26M
Interest expense$2.70M$3.02M$3.80M$6.62M$15.96M$16.44M$19.41M$28.31M$37.70M$45.58M
Pre-tax income$16.45M-$127.79M-$106.29M———————
Income tax$0$0$0$0$0$0$0$0$0$0
Net income$16.45M-$127.79M-$106.29M-$121.69M-$127.29M-$215.31M-$388.95M-$526.24M-$589.53M-$784.96M
EBITDA$19.43M-$111.48M-$87.68M-$97.57M-$92.11M-$184.04M-$318.39M-$484.31M-$526.72M-$602.13M
EPS (basic)$0.41$-2.59$-1.95$-2.11$-1.97$-2.80$-4.33$-5.45$-5.26$-6.54
EPS (diluted)$0.39$-2.59$-1.95$-2.11$-1.97$-2.80$-4.33$-5.45$-5.26$-6.54
Diluted shares42.56M49.40M54.42K57.58K64.52K76.89K89.83K96.52K111.98K120.10K
Operating margin17.6%-848.3%-282.3%-368.0%-168.3%-264.5%-342.8%-6589.7%-2902.7%-695.4%
Net margin15.5%-955.9%-337.4%-452.9%-228.0%-305.7%-411.2%-6988.6%-3191.1%-891.6%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$66.87M$125.21M$42.26M$36.43M$82.98M$112.67M$65.58M$113.02M$94.86M$122.52M
Short-term investments$89.38M$143.69M$156.47M$188.68M$381.07M$358.97M$717.00M$501.80M$981.16M$759.70M
Receivables$24.00K$1.11M$2.23M$5.16M$4.42M$51.82M$147.00K$1.28M$16.65M$17.76M
Inventory—————————$0
Total current assets$158.63M$274.30M$207.67M$233.75M$474.22M$535.67M$795.19M$628.05M$1.11B$916.98M
Total assets$170.14M$294.81M$211.18M$289.81M$533.80M$841.32M$1.01B$824.32M$1.40B$1.42B
Total current liabilities$33.26M$32.44M$22.19M$26.02M$31.20M$71.86M$84.62M$102.68M$179.67M$202.45M
Short-term debt$2.50M$0$2.61M$0$0—$958.00K$10.08M$11.52M$41.18M
Long-term debt$27.38M$31.78M$39.81M$45.05M$46.21M$47.37M$63.81M$58.38M$93.23M$246.38M
Total debt$29.88M$31.78M$42.41M$45.05M$46.21M$47.37M$64.77M$68.46M$104.75M$287.56M
Total liabilities$75.78M$184.97M$185.24M$300.75M$420.42M$597.46M$1.12B$1.21B$1.54B$2.08B
Shareholders' equity$94.36M$109.84M$25.93M-$10.94M$113.38M$243.86M-$107.90M-$386.32M-$135.37M-$659.62M

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$36.98M-$101.76M-$101.22M-$90.91M$8.94M-$142.52M-$299.52M-$414.33M-$395.89M-$510.01M
Capital expenditures$1.60M$2.88M$889.00K$2.62M$11.05M$48.87M$11.34M$1.42M$3.91M$24.81M
Free cash flow$35.39M-$104.64M-$102.10M-$93.53M-$2.11M-$191.39M-$310.85M-$415.75M-$399.80M-$534.82M
Investing cash flow-$52.08M-$65.83M$5.13M-$74.71M-$196.51M-$147.78M-$262.13M$239.25M-$553.10M$16.67M
Financing cash flow$16.89M$225.92M$13.13M$159.79M$234.12M$319.98M$516.17M$221.32M$930.61M$524.46M
Stock-based compensation$7.15M$9.03M$9.76M$10.76M$17.62M$26.83M$47.85M$72.06M$97.84M$112.29M
Depreciation & amortization$741.00K$1.92M$1.24M$1.29M$1.83M$2.28M$5.81M$11.89M$9.53M$10.12M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.